Researcher
Jo Van Ginderachter
- Keywords (Vrije Universiteit Brussel):Applied biological sciences, biotechnology
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Adaptive immunology, Bacteriology
- Disciplines (Vrije Universiteit Brussel):Applied immunology
Affiliations
- Cellular and Molecular Immunology (Research group)
Responsible
From1 Oct 1995 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Jan 2024 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2019 → 31 Dec 2023 - Department of Bio-engineering Sciences (Department)
Member
From8 Apr 2019 → 30 Sep 2019 - Van Ginderachter Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2012 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2010 → 20 Oct 2022 - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 1999 → 30 Sep 2014
Projects
1 - 10 of 26
- Therapeutic targeting of tumor-associated macrophages with anti-CD163 Nanobody-drug conjugates as novel cancer therapyFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Blocking the immunoregulatory family members D-dopachrome tautomerase (D-DT) and Macrophage Migration Inhibitory Factor (MIF) to improve immunotherapy of cancerFrom1 Nov 2022 → TodayFunding: FWO fellowships
- SRP-Onderzoekszwaartepunt: ITAREG: Molecular Imaging and TArgeting of immunoREGulatory cells in Inflammatory diseases and cancerFrom1 Nov 2022 → TodayFunding: BOF - projects
- IOF Accelerator:Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)From1 Oct 2022 → 31 Mar 2024Funding: IOF - technology validation in real environment
- SBO Project : LipoMacs: functional Lipidomics to unlock Macrophage-mediated therapyFrom1 Oct 2022 → TodayFunding: FWO Strategic Basic Research (SBO)
- Tricking tumor immunosuppression: RNA epigenetics as novel target to improve cancer immunotherapyFrom1 Jan 2022 → TodayFunding: FWO EOS
- Optimized anti-Neuropilin-1 Nanobody formats as cancer therapyFrom1 Nov 2021 → TodayFunding: FWO fellowships
- Immunological memory of the macrophage niche (MacNicheMemo).From1 Jan 2021 → TodayFunding: BOF - iBOF
- Blocking Lipocalin-2 (Lcn-2) using Nanobodies as novel cancer therapyFrom1 Nov 2020 → TodayFunding: FWO fellowships
- Seahorse platform: the Agilent Seahorse Flux Analyser with integrated normalization systemFrom1 May 2020 → TodayFunding: Hercules - Small and Medium size research infrastructure
Publications
1 - 10 of 102
- Q586B2 is a crucial virulence factor during the early stages of Trypanosoma brucei infection that is conserved amongst trypanosomatids(2024)
Authors: Benoît Stijlemans, Patrick De Baetselier, Inge Van Molle, Laurence Lecordier, Erika Hendrickx, Ema Romão, Cécile Vincke, Wendy Baetens, Steve Schoonooghe, Gholamreza Hassanzadeh Ghassabeh, et al.
- Lipocalin-2: A Nurturer of Tumor Progression and a Novel Candidate for Targeted Cancer Therapy(2023)
Authors: Maida Živalj, Jo Van Ginderachter, Benoit Stijlemans
- Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)(2023)
Authors: Odrade Gondry, Catarina Xavier, Laurens Raes, Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, Karine Breckpot, Quentin Lecocq, Lore Decoster, Christel Fontaine, et al.
Pages: 1378-1384 - Ontogeny, functions and reprogramming of Kupffer cells upon infectious disease(2023)
Authors: Mohamed Musrati, Patrick De Baetselier, Kiavash Movahedi, Jo Van Ginderachter
- Flt3L therapy increases the abundance of Treg-promoting CCR7+ cDCs in preclinical cancer models(2023)
Authors: Emile Clappaert, Daliya Kancheva, Jan Brughmans, Ayla Debraekeleer, Pauline Bardet, Yvon Elkrim, Dagmar Lacroix, Maida Zivalj, Ahmed E. I. Hamouda, Jo A Van Ginderachter, et al.
- Whole-mouse clearing and imaging at the cellular level with vDISCO(2023)
Authors: Ruiyao Cai, Zeynep Ilgin Kolabas, Chenchen Pan, Hongcheng Mai, Shan Zhao, Doris Kaltenecker, Fabian F Voigt, Muge Molbay, Tzu-Lun Ohn, Cécile Vincke, et al.
Pages: 1197-1242 - Hallmarks of Cancer Affected by the MIF Cytokine Family(2023)
Authors: Romina Mora Barthelmess, Benoît Stijlemans, Jo A Van Ginderachter
Pages: 1-25 - Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting(2023)
Authors: Marco Erreni, Francesca D'Autilia, Roberta Avigni, Evangelia Bolli, Sana M Arnouk, Kiavash Movahedi, Pieterjan Debie, Achille Anselmo, Raffaella Parente, Cécile Vincke, et al.
Pages: 355-373 - Macrophages in the brain(2023)
Authors: Karen De Vlaminck, Jo A Van Ginderachter, Kiavash Movahedi
Number of pages: 173 - Dendritic cell-based cancer immunotherapy: increasing intratumoral dendritic cell abundance and potential for vaccination(2023)
Authors: Emile Clappaert, Damya Laoui, Jo A Van Ginderachter
Number of pages: 171
Patents
1 - 6 of 6
- Tumor-associated dendritic cell preparations and uses thereof (Inventor)
- Non-blocking human ccr8 binders (Inventor)
- Human ccr8 binders (Inventor)
- Anti-macrophage mannose receptor immunoglobulin single variable domains for targeting and in vivo imaging of tumor-associated macrophages (Inventor)
- A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer (Inventor)
- Murine cross-reactive human ccr8 binders (Inventor)